news[Former Asklep] ASKLEP establishes a Joint Venture Company (JVC) aspiring to deliver new services for global clinical trials in Japan.

*Articles from the former Asklep

Asklep Inc. (Headquarters: 3-1-3 Higashi Ikebukuro, Toshima-ku, Tokyo, Japan, Representative Director and President: Hiroshi Ichikawa) and ReSearch Pharmaceutical Services Inc. (RPS, Headquarters: Pennsylvania, U.S., CEO & Chairman: Daniel Perlman), a leading global Contract Research Organisation announced today the creation of the Joint Venture Company (JVC) RPS-Asklep Inc. to deliver global clinical development services in Japan.

About RPS-Asklep Inc.

To meet the increasing needs of global drug development, Asklep provides clinical development services in East Asia with offices across Japan, China, Taiwan, and Korea. RPS provides unique global outsourcing solutions from its accumulated knowledge and knowhow of multinational trials.

This exclusive collaboration will combine RPS’s global solutions and Asklep’s localized solutions to create a new service domain, with expectations of becoming a game changer in the CRO business in Japan and accommodate the specific and evolving needs of the industry.

Commenting upon the announcement, Daniel Perlman, CEO and Founder of RPS Inc said “By combining RPS’ innovative approaches to meeting the industry’s needs with Asklep’s excellent reputation, significant size, and local infrastructure, RPS will be able to meet current and future needs across the biopharmaceutical and medical device industry. Japan is an important market for clinical development and whilst other global CROs have struggled to establish themselves through either loose alliances or home-grown small operations, we have decided that a JVC with teeth brings true ownership and accountability with mutual success and long-term stability”.

Asklep continues to be committed to providing unique, high quality solutions for drug lifecycle management and we are determined to become the HUB for Pharmaceutical Intelligence in the Asian region through our strategic vision of “ACTION for ACTS (Asian Clinical Trials and Solutions)”.

Outline of JVC

Name:RPS-Asklep Inc.
Address:3-1-3 Higshi Ikebukuro, Toshima-ku, Tokyo
Directors:Alan Morgan (CEO),
Yoshiteru Ishikawa (COO)
Service:Clinical Development Services
Establishment:May, 2013
Business is scheduled to start June 1st, 2013.

About RPS

ReSearch Pharmaceutical Services (RPS), the market leading global provider of innovative outsourcing Clinical Development Solutions, provides comprehensive Phase I-IV services to meet the evolving needs of the Biopharmaceutical, Medical Device and Diagnostic industries, customized by customer type (large, mid-size, and small). Built organically, RPS is the fastest growing top 10 global Clinical Research Organization (CRO), with more than 5,000 employees and operations in more than 64 countries with proprietary internal structures. These structures provide both RPS and its partner’s greater development flexibility and growth. RPS is uniquely positioned to provide the following customized clinical development solutions:

  • Large organizations: RPS provides innovative, Embedded, portfolio-wide clinical development solutions  delivering multi-million dollar cost savings , greater quality and the ability to manage more within their portfolio while retaining strategic control and effectively managing regulatory risk.
  • Midsize organizations: RPS has leveraged its market leading Embedded Clinical Development Solutions expertise providing an innovative model that enables the efficient internal development of a midsize company’s product portfolio with greater control and flexibility, accelerated development timelines and substantially reduced costs.
  • Virtual/Small Organizations: RPS provides a comprehensive project based delivery solution with market leading full service processes and tools.  Our in-house drug development expertise combined with outstanding project management means that our clients achieve superior execution on efficiently designed studies.  RPS recruits in excess of 100,000 patients a year with performance ahead of industry leading benchmarks.

 For more information about RPS, visit

For further information, please contact

INTAGE Healthcare Inc.